Clinical–liver, pancreas, and biliary tractProspective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients
Section snippets
Patients
During the last 8 years from January 1994 to December 2001, a total of 72,866 patients with primary liver cancer were newly registered biannually by the Liver Cancer Study Group of Japan throughout some 800 medical institutions using a registration/questionnaire sheet with more than 180 questions. HCC patients occupied 95% (69,182/72,866) of primary liver cancer. Of these, 8542 patients were assigned in the current prospective cohort study, who underwent TACE as an initial treatment for
Results
During an 8-year follow-up period, the total numbers of patient deaths and censored cases were 3605 and 4905, respectively. The number of patients who died and were censored annually was as follows: 1316 and 1939 during year 1, 1067 and 1258 from 1 to 2 years, 630 and 764 from 2 to 3 years, 341 and 454 from 3 to 4 years, 148 and 216 from 4 to 5 years, 72 and 145 from 5 to 6 years, 23 and 81 from 6 to 7 years, and 8 and 48 from 7 to 8 years, respectively.
Discussion
As the background of causal factor of HCC in the current study, hepatitis C virus infection was more prevalent than hepatitis B virus (74% to 11%, respectively). The ratio of hepatitis C virus to hepatitis B virus was almost similar to that reported by a Spanish paper11 and was different from that from Hong Kong where hepatitis B virus was predominant12 and from France where alcohol abuse was the main cause of HCC.8 In relation to the tumor size, small HCC no larger than 2 cm in diameter was
References (54)
- et al.
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
J Hepatol
(2003) - et al.
Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomasa retrospective and nationwide survey in Japan
Hepatology
(2000) - et al.
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial
Gastroenterology
(1988) - et al.
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
J Hepatol
(1990) - et al.
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolizationa multicenter randomized trial
J Hepatol
(1998) - et al.
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinomaa randomised controlled trial
Lancet
(2002) - et al.
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
Hepatology
(2002) - et al.
Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatomaa preliminary report
Eur J Cancer Clin Oncol
(1983) - et al.
Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil
Gastroenterology
(1989) - et al.
Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcoholprospective evaluation of response and survival in a US population
J Vasc Interv Radiol
(1999)
Report of the 16th follow-up survey of primary liver cancer
Hepatol Res
The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy
Eur J Surg Oncol
Sinusoidal embolizationimpact of iodized oil on hepatic microcirculation
J Vasc Interv Radiol
Estimating the world cancer burdenGlobocan 2000
Int J Cancer
Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years
Arch Surg
Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma
Cancer
A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma
N Engl J Med
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinomaresults of a randomized, controlled trial in a single institution
Hepatology
L’embolisation arterielle hepatique dans les tumeurs malignes du foie
Ann Radiol
Transcatheter arterial embolization therapy in unresectable hepatomas—experience in 15 cases
Acta Hepatologica Japonica
Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents
Radiology
Hepatocellular carcinoma detected by iodized oil
Radiology
Hepatocellular carcinomatreatment with intra-arterial iodized oil with and without chemotherapeutic agents
Radiology
A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge
Cancer
Transcatheter oily chemoembolization of hepatocellular carcinoma
Radiology
Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma
Cardiovasc Intervent Radiol
Small hepatocellular carcinomatreatment with subsegmental transcatheter arterial embolization
Radiology
Cited by (749)
Potential of African plants and their derived phytochemicals against hepatocellular carcinoma
2024, Advances in Botanical ResearchBreaking down tumor thrombus: Current strategies for medical management
2023, Thrombosis ResearchASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization
2023, Hepatobiliary and Pancreatic Diseases InternationalEffect of preoperative liver-directed therapy prior to hepatic resection
2023, American Journal of Surgery